Sumitomo Mitsui DS Asset Management Company Ltd lifted its holdings in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 16.1% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 13,860 shares of the biopharmaceutical company’s stock after purchasing an additional 1,927 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in Alexion Pharmaceuticals were worth $1,357,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. We Are One Seven LLC lifted its holdings in Alexion Pharmaceuticals by 5.7% in the second quarter. We Are One Seven LLC now owns 1,586 shares of the biopharmaceutical company’s stock valued at $207,000 after buying an additional 86 shares during the period. Signaturefd LLC lifted its holdings in Alexion Pharmaceuticals by 13.2% in the second quarter. Signaturefd LLC now owns 822 shares of the biopharmaceutical company’s stock valued at $108,000 after buying an additional 96 shares during the period. Fort Washington Investment Advisors Inc. OH lifted its holdings in Alexion Pharmaceuticals by 6.5% in the second quarter. Fort Washington Investment Advisors Inc. OH now owns 1,810 shares of the biopharmaceutical company’s stock valued at $237,000 after buying an additional 111 shares during the period. Verity Asset Management Inc. lifted its holdings in Alexion Pharmaceuticals by 4.1% in the second quarter. Verity Asset Management Inc. now owns 2,842 shares of the biopharmaceutical company’s stock valued at $372,000 after buying an additional 112 shares during the period. Finally, Vision Capital Management Inc. increased its stake in Alexion Pharmaceuticals by 1.1% in the second quarter. Vision Capital Management Inc. now owns 10,482 shares of the biopharmaceutical company’s stock valued at $1,373,000 after purchasing an additional 113 shares in the last quarter. Institutional investors own 93.24% of the company’s stock.

Shares of NASDAQ:ALXN traded down $1.58 during midday trading on Friday, hitting $98.41. 1,405,996 shares of the company’s stock were exchanged, compared to its average volume of 1,741,548. The company has a debt-to-equity ratio of 0.26, a current ratio of 4.04 and a quick ratio of 3.56. The stock has a 50 day moving average price of $101.88 and a 200-day moving average price of $118.85. The company has a market cap of $22.42 billion, a PE ratio of 13.88, a price-to-earnings-growth ratio of 0.95 and a beta of 1.67. Alexion Pharmaceuticals, Inc. has a 12 month low of $92.56 and a 12 month high of $141.86.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its earnings results on Wednesday, July 24th. The biopharmaceutical company reported $2.64 EPS for the quarter, topping the consensus estimate of $2.13 by $0.51. The company had revenue of $1.20 billion during the quarter, compared to the consensus estimate of $1.18 billion. Alexion Pharmaceuticals had a net margin of 29.64% and a return on equity of 20.23%. The firm’s revenue for the quarter was up 15.1% on a year-over-year basis. During the same period in the previous year, the firm posted $2.07 earnings per share. On average, analysts anticipate that Alexion Pharmaceuticals, Inc. will post 9.06 EPS for the current fiscal year.

Several equities research analysts have weighed in on ALXN shares. Robert W. Baird set a $165.00 price target on shares of Alexion Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, August 30th. Piper Jaffray Companies set a $180.00 price target on shares of Alexion Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, September 6th. William Blair started coverage on shares of Alexion Pharmaceuticals in a research note on Thursday, September 26th. They issued an “outperform” rating and a $146.00 price target for the company. Cowen reaffirmed a “buy” rating and issued a $165.00 price target on shares of Alexion Pharmaceuticals in a research note on Wednesday. Finally, BMO Capital Markets started coverage on shares of Alexion Pharmaceuticals in a research note on Thursday, September 12th. They issued an “outperform” rating and a $149.00 price target for the company. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and fifteen have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $159.76.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

Featured Article: Total Return

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.